Tau exhibits unique seeding properties in globular glial tauopathy.
Aggregation
Globular glial tauopathy
Seeding
Tau
Tauopathy
Journal
Acta neuropathologica communications
ISSN: 2051-5960
Titre abrégé: Acta Neuropathol Commun
Pays: England
ID NLM: 101610673
Informations de publication
Date de publication:
07 03 2019
07 03 2019
Historique:
received:
30
01
2019
accepted:
28
02
2019
entrez:
9
3
2019
pubmed:
9
3
2019
medline:
31
3
2020
Statut:
epublish
Résumé
Tauopathies are neurodegenerative disorders characterized by aggregation of microtubule associated tau protein in neurons and glia. They are clinically and pathologically heterogeneous depending on the isoform of tau protein that accumulates (three or four 31-to-32-amino-acid repeats [3R or 4R] in the microtubule binding domain), as well as the cellular and neuroanatomical distribution of tau pathology. Growing evidence suggests that distinct tau conformers may contribute to the characteristic features of various tauopathies. Globular glial tauopathy (GGT) is a rare 4R tauopathy with globular cytoplasmic inclusions within neurons and glial cells. Given the unique cellular distribution and morphology of tau pathology in GGT, we sought to determine if tau species in GGT had distinctive biological properties. To address this question, we performed seeding analyses with postmortem brain tissues using a commercial tau biosensor cell line. We found that brain lysates from GGT cases had significantly higher seeding competency than other tauopathies, including corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and Alzheimer's disease (AD). The robust seeding activity of GGT brain lysates was independent of phosphorylated tau burden and diminished upon removal of tau from samples, suggesting that seeding properties were indeed mediated by tau in the lysates. In addition, cellular inclusions in the tau biosensor cell line induced by GGT had a distinct, globular morphology that was markedly different from inclusions induced by other tauopathies, further highlighting the unique nature of tau species in GGT. Characterization of different tau species in GGT showed that detergent-insoluble, fibril-like tau contained the highest seeding activity, as reflected in its ability to increase tau aggregation in primary glial cultures. Taken together, our data suggest that unique seeding properties differentiate GGT-tau from other tauopathies, which provides new insight into pathogenic heterogeneity of primary neurodegenerative tauopathies.
Identifiants
pubmed: 30845985
doi: 10.1186/s40478-019-0691-9
pii: 10.1186/s40478-019-0691-9
pmc: PMC6404306
doi:
Substances chimiques
tau Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
36Subventions
Organisme : NINDS NIH HHS
ID : R35 NS097273
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG016574
Pays : United States
Organisme : NINDS NIH HHS
ID : U54 NS100693
Pays : United States
Références
Mol Neurodegener. 2017 Jun 29;12(1):50
pubmed: 28662669
Hum Mol Genet. 2015 Nov 1;24(21):6198-212
pubmed: 26276810
Nat Rev Neurosci. 2016 Jan;17(1):5-21
pubmed: 26631930
Annu Rev Neurosci. 2017 Jul 25;40:189-210
pubmed: 28772101
Neurobiol Dis. 2017 Sep;105:74-83
pubmed: 28502805
Acta Neuropathol. 2015 Aug;130(2):199-214
pubmed: 25900293
Hum Mol Genet. 2004 Apr 1;13(7):703-14
pubmed: 14962978
J Neuropathol Exp Neurol. 2014 Jan;73(1):81-97
pubmed: 24335532
J Biol Chem. 2019 Jan 18;294(3):1045-1058
pubmed: 30478174
Neurology. 2005 May 10;64(9):1578-85
pubmed: 15883319
Mol Neurodegener. 2016 May 12;11(1):38
pubmed: 27176225
J Neuropathol Exp Neurol. 2016 Dec 1;75(12):1100-1109
pubmed: 27678346
PLoS One. 2010 May 25;5(5):e10810
pubmed: 20520830
Neuron. 2016 Nov 23;92(4):796-812
pubmed: 27974162
J Exp Med. 2016 Nov 14;213(12):2635-2654
pubmed: 27810929
Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):E4376-85
pubmed: 25261551
Nature. 2018 Sep;561(7721):137-140
pubmed: 30158706
Nature. 2017 Jul 13;547(7662):185-190
pubmed: 28678775
J Biol Chem. 2017 Sep 15;292(37):15277-15286
pubmed: 28760828
J Exp Neurosci. 2016 Feb 10;9(Suppl 2):43-50
pubmed: 26884683
Neuropathology. 2014 Dec;34(6):555-70
pubmed: 25124031
Neuron. 2016 Jun 1;90(5):941-7
pubmed: 27210553
Am J Pathol. 2017 Jun;187(6):1399-1412
pubmed: 28408124
Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9535-40
pubmed: 23690619
J Biol Chem. 2018 Feb 16;293(7):2408-2421
pubmed: 29259137
Neuropathol Appl Neurobiol. 2015 Feb;41(1):3-23
pubmed: 25495175
Neuron. 2014 Jun 18;82(6):1271-88
pubmed: 24857020
Sci Data. 2018 Mar 13;5:180036
pubmed: 29533394
N Engl J Med. 2015 Jan 15;372(3):249-63
pubmed: 25587949
Acta Neuropathol. 2011 Oct;122(4):415-28
pubmed: 21773886
Nature. 2018 May;557(7706):558-563
pubmed: 29743672
J Biol Chem. 2015 Jan 9;290(2):1049-65
pubmed: 25406315
Cell Rep. 2018 Apr 17;23(3):709-715
pubmed: 29669277
Acta Neuropathol. 2013 Oct;126(4):537-544
pubmed: 23995422
J Neurosci. 2017 Nov 22;37(47):11406-11423
pubmed: 29054878
Mol Neurodegener. 2018 Oct 4;13(1):52
pubmed: 30286791
Trends Biotechnol. 2016 Oct;34(10):825-834
pubmed: 26996615